SCM
AKBA icon

Sterling Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Sterling Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.6K Sell
7,632
-5,525
-42% -$7.59K ﹤0.01% 2340
2025
Q4 		$21.2K Sell
13,157
-2,248
-15% -$4.71K ﹤0.01% 2197
2025
Q3 		$42.1K Buy
15,405
+9,356
+155% +$31.1K ﹤0.01% 1815
2025
Q2 		$22K Buy
6,049
+2,639
+77% +$7.25K ﹤0.01% 1761
2025
Q1 		$6.55K Sell
3,410
-2,654
-44% -$5.42K ﹤0.01% 2026
2024
Q4 		$11.5K Buy
6,064
+5,445
+880% +$9.46K ﹤0.01% 2102
2024
Q3 		$817 Buy
+619
New +$827 ﹤0.01% 2644
2018
Q2 		– Sell
-32,425
Closed -$309K – 840
2018
Q1 		$309K Buy
+32,425
New +$454K ﹤0.01% 795
2017
Q4 		– Sell
-42,903
Closed -$844K – 876
2017
Q3 		$844K Buy
+42,903
New +$660K 0.01% 677

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Sterling Capital Management's AKBA Position: Q1 2026 in Review

Sterling Capital Management reduced its Akebia Therapeutics (AKBA) stake by 42% in Q1 2026, selling an estimated $7.59K and leaving 7,632 shares worth $10.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2340.

Sterling Capital Management first reported a position in AKBA in Q3 2017 and has held it in 9 quarters since. The position peaked at $844K in Q3 2017. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Sterling Capital Management held 7,632 shares of Akebia Therapeutics worth $10.6K as of Q1 2026.
  • Sterling Capital Management sold 5,525 Akebia Therapeutics shares in Q1 2026, an estimated $7.59K.
  • Akebia Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2340 holding.
  • Sterling Capital Management first reported a position in Akebia Therapeutics in Q3 2017 and has held it in 9 quarters since.
  • Sterling Capital Management's Akebia Therapeutics position peaked at $844K in Q3 2017.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.